SEC Form 4 · accession 0001250853-16-000132
IOVANCE BIOTHERAPEUTICS, INC. · IOVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James G. Bender
Officer — Vice President - Manufacturing
Period of report
Mar 11, 2016
Accepted (ET)
Mar 15, 2016 · 7:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001425205
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $5.05 | Mar 11, 2016 | A | 30,000 | A | — | Mar 11, 2026 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The option will vest as to 10,000 shares on March 11, 2017, and the remaining 20,000 shares will vest quarterly over the next two years after March 11, 2017, provided the Reporting Person is still providing services to the Issuer on the respective dates.